New Janssen distribution hub consolidates European supply chain

Janssen Pharmaceutica is making its European supply chain operations more efficient with a new distribution hub in Belgium that funnels production from a number of European plants into a single location.

It is the second piece of manufacturing and distribution news to come from the Johnson & Johnson ($JNJ) subsidiary this week. The company also said it is expanding production at three manufacturing plants in Puerto Rico.

Janssen invested €49 million ($63.5 million) in the 21,500-square-meter distribution facility in La Louvière, where it has consolidated the operations of 15 logistics centers, the company says. The drugs can then be shipped to Janssen companies in 11 European countries and then to other operations outside of Europe. The operation, which will employ 115, is expected to ship about 385,000 orders annually, equating to about 160 million packs.

Janssen also kept the environment in mind when it constructed the facility, using wood from sustainable logging and regional and renewable materials. The company said solar panels will be installed next year.

Earlier this week, Johnson & Johnson said it would invest about $225 million to expand manufacturing capacity at four plants in Puerto Rico, three of them Janssen drug plants and one a medical device plant. Those additions will add more than 300 jobs, offsetting the 200 jobs lost at an over-the-counter drug plant in Puerto Rico after investments there made it more efficient.

- here's the release

Related Articles:
J&J investing $225 million in 4 Puerto Rico plants 
J&J 'decree' upgrades cost 200 jobs in Puerto Rico

Suggested Articles

Cambrex has completed installation of multiple continuous flow reactor platforms at its facility in High Point, North Carolina.

Australia’s Mayne Pharma has opened its $80 million oral solid-dose manufacturing facility in Greenville, North Carolina.

GE is launching its prefab line of drug manufacturing units that will help biopharma companies produce viral vector-based vaccines.